Key terms
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RCKT news
Apr 02
11:50am ET
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)
Apr 02
6:07am ET
Rocket announces EMA accepted MAA for RP-L102 lentiviral
Apr 02
5:15am ET
Hold Rating on Rocket Pharmaceuticals Amid Market Opportunity and Efficacy Questions for RP-A501
Apr 02
5:11am ET
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)
Apr 02
5:00am ET
Analysts Offer Insights on Healthcare Companies: Q32 Bio (QTTB) and Rocket Pharmaceuticals (RCKT)
Apr 02
4:56am ET
Rocket Pharmaceuticals initiated with a Neutral at Goldman Sachs
Mar 29
5:32pm ET
Rocket Pharmaceuticals Welcomes New CFO Aaron Ondrey
Mar 26
4:03pm ET
Rocket Pharmaceuticals names Aaron Ondrey as new CFO
Mar 01
12:55pm ET
JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
Mar 01
10:02am ET
JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
Feb 28
7:16am ET
Rocket Pharmaceuticals price target lowered to $49 from $50 at Canaccord
Feb 27
11:39pm ET
Robust Financials and Pipeline Progress Secure Buy Rating for Rocket Pharmaceuticals
Feb 27
4:55pm ET
Buy Rating Affirmed for Rocket Pharmaceuticals Amid Promising Pipeline and Upcoming Commercial Launch
Feb 27
8:40am ET
Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)
Feb 27
7:48am ET
Rocket Pharmaceuticals (RCKT) Receives a Buy from Stifel Nicolaus
Feb 27
6:30am ET
Buy Rating Affirmed for Rocket Pharmaceuticals Amidst Strategic Progress and Solid Financials
Feb 27
4:55am ET
Rocket Pharmaceuticals: A Strong Buy Amidst Upcoming Catalysts and Regulatory Milestones
Feb 26
9:35pm ET
Optimistic Buy Rating for Rocket Pharmaceuticals Amidst Strategic Regulatory Advancements and Trial Progress
Feb 26
4:05pm ET
Rocket Pharmaceuticals reports Q4 EPS (64c), consensus (79c)
Feb 13
4:54pm ET
Rocket Pharmaceuticals’ KRESLADI Review Extended by FDA
Feb 13
4:31pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Rocket Pharmaceuticals (RCKT)
Feb 13
4:29pm ET
Buy Rating for Rocket Pharmaceuticals Based on Strong Gene Therapy Pipeline and Near-Term Value Drivers
Feb 13
11:20am ET
Analysts Offer Insights on Healthcare Companies: ESSA Pharma (EPIX) and Rocket Pharmaceuticals (RCKT)
Feb 13
10:15am ET
William Blair Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
No recent press releases are available for RCKT
RCKT Financials
Key terms
Ad Feedback
RCKT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RCKT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
